Intergroup Hodgkin's disease in children study of stages I and II: A preliminary report

M. P. Sullivan, L. M. Fuller, T. Chen, R. Fisher, C. Fryer, E. Gehan, G. S. Gilchrist, D. Hays, W. Hanson, R. Heller, G. Higgins, D. Jenkin, F. Kung, W. Sheehan, M. Tefft, J. Ternberg, M. Wharam

Research output: Contribution to journalArticle

Abstract

The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23% of the staging procedures reviewed were nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.

Original languageEnglish (US)
Pages (from-to)937-947
Number of pages11
JournalCancer Treatment Reports
Volume66
Issue number4
StatePublished - 1982
Externally publishedYes

Fingerprint

Hodgkin Disease
Radiotherapy
Mediastinal Diseases
Groin
Therapeutic Uses
Therapeutics
Documentation
Neck
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sullivan, M. P., Fuller, L. M., Chen, T., Fisher, R., Fryer, C., Gehan, E., ... Wharam, M. (1982). Intergroup Hodgkin's disease in children study of stages I and II: A preliminary report. Cancer Treatment Reports, 66(4), 937-947.

Intergroup Hodgkin's disease in children study of stages I and II : A preliminary report. / Sullivan, M. P.; Fuller, L. M.; Chen, T.; Fisher, R.; Fryer, C.; Gehan, E.; Gilchrist, G. S.; Hays, D.; Hanson, W.; Heller, R.; Higgins, G.; Jenkin, D.; Kung, F.; Sheehan, W.; Tefft, M.; Ternberg, J.; Wharam, M.

In: Cancer Treatment Reports, Vol. 66, No. 4, 1982, p. 937-947.

Research output: Contribution to journalArticle

Sullivan, MP, Fuller, LM, Chen, T, Fisher, R, Fryer, C, Gehan, E, Gilchrist, GS, Hays, D, Hanson, W, Heller, R, Higgins, G, Jenkin, D, Kung, F, Sheehan, W, Tefft, M, Ternberg, J & Wharam, M 1982, 'Intergroup Hodgkin's disease in children study of stages I and II: A preliminary report', Cancer Treatment Reports, vol. 66, no. 4, pp. 937-947.
Sullivan MP, Fuller LM, Chen T, Fisher R, Fryer C, Gehan E et al. Intergroup Hodgkin's disease in children study of stages I and II: A preliminary report. Cancer Treatment Reports. 1982;66(4):937-947.
Sullivan, M. P. ; Fuller, L. M. ; Chen, T. ; Fisher, R. ; Fryer, C. ; Gehan, E. ; Gilchrist, G. S. ; Hays, D. ; Hanson, W. ; Heller, R. ; Higgins, G. ; Jenkin, D. ; Kung, F. ; Sheehan, W. ; Tefft, M. ; Ternberg, J. ; Wharam, M. / Intergroup Hodgkin's disease in children study of stages I and II : A preliminary report. In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 4. pp. 937-947.
@article{bd166f3e682b48f5afb25d3eac5acfd2,
title = "Intergroup Hodgkin's disease in children study of stages I and II: A preliminary report",
abstract = "The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95{\%} are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23{\%} of the staging procedures reviewed were nonevaluable and 28{\%} of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.",
author = "Sullivan, {M. P.} and Fuller, {L. M.} and T. Chen and R. Fisher and C. Fryer and E. Gehan and Gilchrist, {G. S.} and D. Hays and W. Hanson and R. Heller and G. Higgins and D. Jenkin and F. Kung and W. Sheehan and M. Tefft and J. Ternberg and M. Wharam",
year = "1982",
language = "English (US)",
volume = "66",
pages = "937--947",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Intergroup Hodgkin's disease in children study of stages I and II

T2 - A preliminary report

AU - Sullivan, M. P.

AU - Fuller, L. M.

AU - Chen, T.

AU - Fisher, R.

AU - Fryer, C.

AU - Gehan, E.

AU - Gilchrist, G. S.

AU - Hays, D.

AU - Hanson, W.

AU - Heller, R.

AU - Higgins, G.

AU - Jenkin, D.

AU - Kung, F.

AU - Sheehan, W.

AU - Tefft, M.

AU - Ternberg, J.

AU - Wharam, M.

PY - 1982

Y1 - 1982

N2 - The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23% of the staging procedures reviewed were nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.

AB - The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of Hodgkin's disease in children has assessed 305 patients. Of these, 279 were 'not ineligible' (no immediate cause for disqualification). Among 223 randomized patients, 144 were evaluable, 131 had documentation of complete or partial remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized patients with favorable presentations (unilateral upper neck, unilateral inguinal, or massive mediastinal disease), 29 had documented remission, two relapsed, and none died. Length of initial disease control (LIDC) was used to measure duration of response. LIDC was best in patients given IF plus MOPP, and 95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the disease characteristics prognostic for response (stage, histologic subtype, and presence of symptoms), only the last factor had a statistically significant effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using criteria developed by the committee, 23% of the staging procedures reviewed were nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The necessity for criteria for evaluation of staging and treatment is certain. Length of followup is too short for correlations of treatment with significant late effects and for relevant therapeutic recommendations.

UR - http://www.scopus.com/inward/record.url?scp=0020079418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020079418&partnerID=8YFLogxK

M3 - Article

C2 - 7042092

AN - SCOPUS:0020079418

VL - 66

SP - 937

EP - 947

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -